Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Leukemia & lymphoma Year : 2021

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

Clarisse Cazelles
  • Function : Author
Karim Belhadj
  • Function : Author
Hélène Vellemans
  • Function : Author
Vincent Camus
  • Function : Author
Elsa Poullot
  • Function : Author
Philippe Gaulard
  • Function : Author
Liana Veresezan
  • Function : Author
Stéphanie Becker
  • Function : Author
Muriel Carvalho
  • Function : Author
Jehan Dupuis
  • Function : Author
Fabien Le Bras
  • Function : Author
François Lemonnier
  • Function : Author
Louise Roulin
  • Function : Author
Taoufik El Gnaoui
  • Function : Author
Fabrice Jardin
  • Function : Author
Nicolas Mounier
  • Function : Author
Hervé Tilly
  • Function : Author
Corinne Haioun
  • Function : Author

Dates and versions

hal-04395393 , version 1 (15-01-2024)

Identifiers

Cite

Clarisse Cazelles, Karim Belhadj, Hélène Vellemans, Vincent Camus, Elsa Poullot, et al.. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leukemia & lymphoma, 2021, 62 (9), pp.2161-2168. ⟨10.1080/10428194.2021.1901090⟩. ⟨hal-04395393⟩

Collections

IMRB UPEC
2 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More